JB Chemicals & Pharmaceuticals (JBCPL) has received an approval from the US Food and Drug Administration (USFDA) for Abbreviated New Drug Application (ANDA) for Midodrine Hydrochloride Tablets USP 2.5 mg, 5 mg and 10 mg. (for treatment of orthostatic hypotension).
The company plans to commercialize this product in Q1 of next financial year and is expected to boost company’s US sales. The company is focused on US business and this approval will help company grow its exports.
JB Chemicals & Pharmaceuticals (JBCPL) is engaged in manufacturing of pharmaceutical specialties in various dosage forms, herbal remedies, diagnostics, generic drugs, active pharmaceutical ingredients (APIs).
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.